filgotinib

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2014-2018
012320142018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Drugs in amorphous solid dispersions (ASDs) are highly dispersed in hydrophilic polymeric carriers, which also help to restrain… (More)
Is this relevant?
2017
2017
OBJECTIVES To evaluate the efficacy and safety of different doses and regimens of filgotinib, an oral Janus kinase 1 inhibitor… (More)
Is this relevant?
2017
2017
BACKGROUND Filgotinib (GLPG0634, GS-6034) is a once-daily, orally administered, Janus kinase 1 (JAK1)-selective inhibitor. The… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Review
2017
Review
2017
INTRODUCTION Biologics were the first targeted therapies for rheumatoid arthritis (RA), having in common high clinical efficacy… (More)
Is this relevant?
2017
2017
OBJECTIVES To evaluate the efficacy and safety of different doses of filgotinib, an oral Janus kinase 1 inhibitor, as monotherapy… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 2
Is this relevant?
2017
2017
An old sedative and hypnotic bromovalerylurea (BU) has anti-inflammatory effects. BU suppressed nitric oxide (NO) release and… (More)
Is this relevant?
2016
2016
OBJECTIVE The selective Janus kinase 1 inhibitor filgotinib (GLPG0634), which is currently in clinical development for the… (More)
Is this relevant?
2015
2015
BACKGROUND AND OBJECTIVES Filgotinib (GLPG0634) is a selective inhibitor of Janus kinase 1 (JAK1) currently in development for… (More)
  • figure 1
  • table 2
  • table 3
  • figure 2
  • figure 3
Is this relevant?
2015
2015
In response to the letter from Dr. Nuggehally R. Srinivas titled ‘‘Comment on: ‘‘Pharmacokinetics and Pharmacokinetic… (More)
Is this relevant?
2014
2014
Janus kinases (JAK1, JAK2, JAK3, and TYK2) are involved in the signaling of multiple cytokines important in cellular function… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?